Nintedanib

Drug Profile

Nintedanib

Alternative Names: BIBF-1120; Intedanib; Ofev; Vargatef

Latest Information Update: 22 Jul 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; European Organisation for Research and Treatment of Cancer; Roswell Park Cancer Institute
  • Class Acetamides; Antifibrotics; Antineoplastics; Esters; Indoles; Piperazines; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Protein tyrosine kinase inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Interstitial lung diseases; Systemic scleroderma; Idiopathic pulmonary fibrosis; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic pulmonary fibrosis; Non-small cell lung cancer
  • Phase III Colorectal cancer; Interstitial lung diseases; Mesothelioma; Ovarian cancer; Systemic scleroderma
  • Phase II Bladder cancer; Endometrial cancer; Hepatocellular carcinoma; Renal cell carcinoma; Soft tissue sarcoma
  • Phase I Fallopian tube cancer; Peritoneal cancer; Solid tumours
  • No development reported Multiple myeloma
  • Discontinued Prostate cancer

Most Recent Events

  • 07 Jul 2017 Phase-II clinical trials in Soft tissue sarcoma (Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in France, Poland, Spain (PO) (NCT02808247)
  • 14 Jun 2017 Final adverse events and pharmacokinetic data from a phase-I trial (In volunteers) presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 06 Jun 2017 Updated efficacy and adverse events data from the phase II LUME-Meso trial in malignant pleural mesothelioma presented at the American Society of Clinical Oncology Annual Meeting (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top